Prostaglandin Analog
Cross-indication landscape: approved drugs, active Phase 3, sponsors, and upcoming readouts.
About Prostaglandin Analog
Prostaglandin Analog drugs are a class of therapeutics that mimic the action of naturally occurring prostaglandins, which are lipid compounds involved in various physiological processes. These analogs primarily function by binding to specific prostaglandin receptors, leading to downstream effects that can modulate inflammation, blood flow, and tissue remodeling. The initial development of this class focused on their potent effects on smooth muscle and vascular tone.
The therapeutic applications for Prostaglandin Analogs are diverse, with approvals spanning critical care, reproductive health, and ophthalmology. In cardiovascular medicine, alprostadil (PROSTIN VR PEDIATRIC) has been a cornerstone treatment for maintaining ductal patency in newborns with congenital heart defects like pulmonary atresia and pulmonary stenosis. In obstetrics, dinoprostone (PREPIDIL, CERVIDIL) is utilized for cervical ripening and labor induction.
The field is increasingly focused on ophthalmology, where prostaglandin analogs like latanoprost (XALATAN), travoprost (TRAVATAN Z), and bimatoprost (LATISSE) have revolutionized the management of glaucoma and ocular hypertension by reducing intraocular pressure. The ongoing research and development suggest a continued expansion of indications and refinement of existing therapies, aiming for improved efficacy and patient outcomes.
18 FDA-approved Prostaglandin Analog drugs, including CERVIDIL, with 13 active Phase 3 trials across 4 indications from 3 active sponsors. Explore approved drugs, the cross-indication pipeline, sponsors, and the Phase 3 readout calendar below.
Approved Prostaglandin Analog Drugs
18 totalThe Prostaglandin Analog class originated with drugs like alprostadil, first approved in 1981 for pediatric cardiovascular conditions, followed by dinoprostone in 1992 for obstetrical use. The significant expansion into ophthalmology began in 1996 with the approval of latanoprost (XALATAN), which established a new standard for managing elevated intraocular pressure. Subsequent generations of prostaglandin analogs in ophthalmology, such as travoprost (TRAVATAN Z) and tafluprost (ZIOPTAN), aimed to offer comparable or improved efficacy, often with subtle differences in receptor binding or metabolic profiles, allowing for varied dosing schedules and patient suitability. Individual Prostaglandin Analog drugs exhibit key differentiators. In glaucoma, latanoprost, travoprost, and tafluprost are all potent agonists of the FP receptor, but they vary in their pharmacokinetics, formulation, and specific indications. For instance, travoprost is available in a preserved formulation (TRAVATAN Z) and an unpreserved one, while bimatoprost, initially approved for eyelash growth (LATISSE), also has an approved indication for glaucoma (DURYSTA), offering a unique mechanism as a sustained-release intracameral implant. The choice between these agents often depends on patient response, tolerability, and prescriber preference, with some head-to-head studies suggesting marginal differences in efficacy or side effect profiles. Today, Prostaglandin Analogs are a cornerstone therapy for open-angle glaucoma and ocular hypertension, frequently used as first-line treatment due to their efficacy and once-daily dosing convenience. The market is mature, with significant generic penetration for older agents like latanoprost and travoprost. AbbVie's DURYSTA represents a newer modality with its intracameral bimatoprost implant, offering a different approach for patients who may not respond well to topical drops or have adherence issues. Class-wide side effects, such as conjunctival hyperemia and iris pigmentation changes, remain a consideration in long-term management.
Prostaglandin Analog Indications in Trials
Active industry trialsThe current Prostaglandin Analog pipeline shows the highest concentration of activity in ophthalmology, specifically targeting Open Angle Glaucoma and Ocular Hypertension, with two active Phase 2/3 trials each. This reflects the established success of the class in these indications and ongoing efforts to refine treatments or develop novel delivery systems. Beyond ophthalmology, there is limited but notable activity in cardiovascular indications, including End Stage Cardiac Failure and HFrEF - Heart Failure With Reduced Ejection Fraction, each with one active trial, suggesting a potential resurgence of interest in their vasodilatory properties for these complex conditions. The expansion frontier for Prostaglandin Analogs is notably exploring new therapeutic areas beyond their traditional ophthalmological and obstetrical uses. The presence of trials in Alopecia Areata indicates an investigation into their effects on hair growth, building on observations from LATISSE. The exploration in cardiovascular diseases suggests a renewed focus on their hemodynamic effects. While specific combination regimens or novel patient subpopulations are not detailed in the provided data, the diversity of indications hints at a broader exploration of prostaglandin receptor modulation for various unmet medical needs, potentially moving beyond topical applications to more systemic or targeted delivery methods. Looking ahead to the next 6-12 months, key readouts are anticipated from the ongoing trials in glaucoma and ocular hypertension, which could validate new formulations or delivery methods. The limited activity in cardiovascular indications suggests that these areas remain more exploratory, and significant breakthroughs may take longer. The pipeline appears moderately active, with a strong foundation in ophthalmology but a more nascent exploration in other fields. The absence of numerous early-stage trials in new indications might suggest a cautious approach to expanding the class, or that significant preclinical work is ongoing before public disclosure.
Top Prostaglandin Analog Sponsors
Industry trials, any indicationGlaukos Corporation is a prominent player in the Prostaglandin Analog space, currently leading with one active Phase 2/3 trial for travoprost (IDOSE TR) targeting Open-Angle Glaucoma and Ocular Hypertension. This leadership stems from their focus on innovative drug delivery systems, as evidenced by IDOSE TR, which aims to provide sustained release of travoprost, potentially improving patient compliance and long-term efficacy compared to daily topical drops. Their strategic investment in this established therapeutic class through advanced technology positions them to capture market share. Other key sponsors actively challenging the landscape include Biopeutics Co., Ltd, Santen Pharmaceutical Co., Ltd., and Egymedicalpedia, each with one active trial. Santen, a well-established ophthalmology company, is likely leveraging its expertise to develop next-generation treatments or explore new indications for prostaglandin analogs. Glaukos Corporation's focus on travoprost, an established generic, suggests a strategy of differentiation through delivery innovation rather than novel molecule discovery. The presence of multiple sponsors indicates a competitive environment, particularly in the lucrative glaucoma market. The strategic landscape for Prostaglandin Analogs is characterized by a mix of established pharmaceutical giants and specialized biotech firms. While the provided data doesn't explicitly detail geographic focus, the presence of companies like THEA PHARMA suggests a global reach. Upcoming catalysts will likely involve clinical trial readouts, particularly from Glaukos, which could validate their sustained-release technology. For investors and BD scouts, the key takeaway is the continued innovation within a mature drug class, driven by novel delivery mechanisms and a persistent focus on ophthalmology, alongside emerging interest in cardiovascular applications. This suggests opportunities for partnerships or acquisitions focused on enhancing existing therapies.
Prostaglandin Analog Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved Prostaglandin Analog drugs across 1 indication from 1 sponsor. Earliest readout: Q4 2029.
Coverage: trials whose intervention is an approved Prostaglandin Analog drug. Pre-approval candidates with development codes are not yet linked.
Methodology
Approved drugs sourced from FDA `pharmClassEpc` (Established Pharmacologic Class) labeling. Active industry trials matched by intervention name (brand or generic) — same coverage approach as our target pages, with the same limitation: pre-approval candidates using development codes won't match until they're approved.
"Active" = RECRUITING / ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING. Sponsor counts include any company running at least one active industry trial.